While all eyes and ears are focused on COVID-19 and beating this pandemic, the administration has pursued harmful policy changes that we can’t let slip under the radar. In two back-to-back regulatory actions in recent months, the administration has taken steps to make it harder for biopharmaceutical manufacturers to offer assistance to commercially insured patients. Why do these changes matter? Both could lead to patients being forced to pay more out of pocket for their medicines in the middle of a public health and economic crisis, when we should be doing the exact opposite - finding ways to lower costs for patients.
- First Action: 2021 Notice of Benefit and Payment Parameters (NBPP) Final Rule. The administration included a policy change in this final rule – a complete reversal from a policy finalized last year – that allows commercial market health plans to exclude the value of manufacturer cost-sharing assistance from counting toward patients’ out-of-pocket maximums, a practice called accumulator adjustment programs. This policy could result in patients shouldering a larger out-of-pocket cost burden for their medicines and, therefore, discontinuing treatment. The use of accumulator adjustment programs is one of the latest schemes health plans are using to avoid working like real insurance, forcing patients to pick up more of the tab even when they have insurance. And while the administration claimed that increased use of accumulator adjustment programs would be unlikely to result from the 2021 NBPP, the Business Group on Health’s just-released annual Health Care Strategy and Plan Design Survey found that nearly 50% of large employers plan to implement copay accumulator programs in 2021 to block the impact of manufacturer cost-sharing assistance, up from 39% using them in 2020.”
- Second Action: Medicaid Proposed Rule. The administration is proposing yet another way to make it more difficult for manufacturers to offer assistance to patients. Currently, manufacturer cost-sharing assistance can be exempted from provisions in Medicaid which are used to determine manufacturer rebates paid to Medicaid programs. Such assistance can be exempted because cost-sharing assistance is provided to patients not health plans or other third parties. The administration is now proposing that manufacturers must “ensure” that this assistance is provided entirely to patients. Unfortunately, through accumulator adjustment programs, health plans can misappropriate patient assistance – a practice ironically supported by the administration’s 2021 NBPP final rule. Therefore, it is very difficult if not impossible for manufacturers to either know about or prevent health plans from misappropriating patient assistance in this way. If the proposal is finalized, the value of the patient assistance will become a part of the calculation of the manufacturer’s Medicaid rebate, likely increasing the amount the manufacturer owes. Requiring this of manufacturers, despite health plans being the ones that interfere with patient assistance, ignores how manufacturer assistance works and would effectively penalize manufacturers that provide assistance to help patients pay their out-of-pocket costs for medicines.
No one should struggle to afford their medicines, yet more and more Americans are facing higher out-of-pocket costs as a result of changes in insurance benefit design. To truly fix the system and address patient affordability challenges, we need long-term solutions like lowering patient cost sharing, reforming the rebate system, and requiring plans to count cost-sharing assistance toward deductibles and out-of-pocket limits rather than excluding it from these calculations. In the meantime, biopharmaceutical manufacturers have stepped up to help patients by providing a broad range of patient assistance in the form of coupons, refund / rebate programs, and cost-sharing assistance directly to patients to use when they pick up their medicines at the pharmacy counter.
Studies have shown that low out-of-pocket costs are associated with improved medicine adherence, which is critical to help ensure better health outcomes. In fact, in 2017, 69% of commercially insured patients did not fill a new prescription when out-of-pocket costs exceeded $250. Conversely, less than 15% of patients abandoned their prescriptions when out-of-pocket costs were under $30. And for some patients, patient assistance programs can make the difference between whether a patient picks up a medicine or not. A recent analysis, for example, found that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their out-of-pocket costs.
Rather than rushing to advance policies that could ultimately increase patients’ financial burdens, the administration should fully consider the negative impacts these changes could have of patients and stop their assault on cost-sharing assistance.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
Delivering breakthroughs and lower costs for patients
The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid
Ensuring access to affordable medicines for patients through Medicaid
CMS, don’t fall behind the rest of the medical community on obesity
The real cost of denying access to medicines in Medicaid
Reimagining patient access through meaningful policy reform
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
Don’t put the government between patients and their medicines
Medicaid by the numbers
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
Ongoing federal probes shed light on PBM and insurer practices
WTAS: The consequences of consolidation and vertical integration
Providing affordable access to medicines in Medicaid
Insurance data: PBM reform has no material impact on premiums
Four years later, Maryland board still hasn’t delivered for patients
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
ICYMI: When middlemen get in the way, it’s the patients who lose
Increased use of prior authorization in Medicaid is blocking access for patients
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
One year to Election Day: Four voter priorities to watch
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
Medicare Prescription Payment Plan will benefit patients if implemented correctly
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
Manufacturers provided $42 billion in Medicaid discounts in 2021 alone
CMS should rethink proposed changes to the Medicaid Drug Rebate Program | PhRMA
Three things to know from the latest Patient Experience Survey
ICYMI: PBM exec admits choosing profits over patients
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
4 key facts on medicine prices and spending
4 Things to know about PhRMA’s new 50-state poll
Americans want state policymakers to lower out-of-pocket costs
Three facts about health care spending
States can support access to medicine as COVID-19 Public Health Emergency ends
Arkansas puts patients first with new share the savings law
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
Holding pharmacy benefit managers accountable
Stopping pharmacy benefit managers from “gaming the system”
Senate hearing to examine bipartisan reforms to rein in middlemen
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
Study finds hepatitis C cure saved Medicaid $15 billion
In their own words: Financial barriers exacerbate access challenges for insured Americans
Putting Delaware patients first: Protecting Patient Assistance Programs
New data show how insurers and middlemen shift Rx costs onto patients
In their own words: Insured Americans struggle to navigate complex coverage
Many seniors are paying more for Part D medicines than their insurer
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
Busting 3 Myths About Copay Coupons
Mental Illness Awareness Week – A time for reflection
A key fact the White House is reluctant to admit
A key fact the White House is reluctant to admit
Navigating the patient experience: Burdens and barriers standing between patients and their care
Making coupons count for patients at the pharmacy counter
Making coupons count for patients with HIV
The Senate’s latest price setting proposal will undermine: Our health care system
The Senate’s latest price setting proposal will undermine: Patient access to medicines
Survey Says: Prescription drug prices are not fueling inflation concerns for Americans
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
Patients win as West Virginia implements first-in-nation share the savings policy
3 things voters are concerned about when it comes to their health care coverage
Copay assistance is a lifeline for patients. So why are insurers blocking it?
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
New poll shows voters sounding the alarm on health insurance companies and PBMs
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
Study finds insurance barriers disproportionately burden patients with chronic illness
What’s really happening when it comes to prescription drug costs
5 public opinion polling trends to watch
Analysis: States can help patients save nearly $1,000 annually on their medicines
New analysis confirms hospitals markup prices for oncology therapies
How standardized plans can improve patients’ access to medicines
The patient experience: Uncovering the barriers to care for insured Americans
Correcting the record: Putting medicine costs and spending in context
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved
Medicaid 101: Three charts on access and spending
Government price setting won’t stop insurers from shifting costs to patients
New comments outline ways to counteract cost-shifting insurance trends
Patients need to pay less for their medicines. States can help.
It’s a new year, but sadly Congress is still pursuing flawed price setting policies
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
New study finds more than half of brand medicine spending goes to the supply chain and others
Making medicines more affordable: Making insurance work like insurance
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
What is missing in the current drug pricing plan
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
Making medicines more affordable: Sharing savings at the pharmacy counter
Three things to know about so-called Medicare negotiation polling
Making Medicines More Affordable: Making coupons count
What they are saying: Government price setting for medicines is not the answer
Four things to know from IQVIAs latest report
The patient experience: Insurance design hurdles lead to access issues for too many Americans
The patient experience: Out-of-pocket costs are driving patients affordability and access challenges
New report shows 3 in 10 Americans that have insurance still face a financial barrier to care
Industry leaders discuss the impact of the drug pricing debate
Five reasons tying VA prices to Medicare Part D misses the mark
America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach
ICYMI: Event spotlights how we can make Medicare work better for patients
The future of the rebate rule: Will policymakers stand with patients?
Celebrating Medicare’s 56th anniversary
3 factors impacting medication adherence for patients with diabetes
New reports shed light on key facts about medicines and affordability
Out-of-pocket trends in Medicare Part D show rising costs for seniors
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
New data from insurers show detriments of copay accumulator adjustment programs
West Virginia becomes the first state to lower patient costs by sharing the savings
Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter
Top five issues voters want addressed in the administration’s first 100 days
Insurers shift medicine costs to patients with severe chronic illnesses
Tennessee’s Medicaid demonstration fails patients
The latest misleading “poll” on drug pricing
Election insights: Common ground areas to address Americans’ health care concerns
New insulin report highlights how incentives benefit middlemen, harm patients
Key facts: The final rebate rule will be a positive change for patients
Election insights: Voter priorities in the states
Insights from the election: Meeting voters where they are on health care
Final rebate rule represents right way to change Medicare
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
Deep dive: The issues that drove the 2020 vote
Voters want to address the real drivers of health care costs for patients and the system
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Study finds middlemen excluded nearly 850 medicines from formularies this year
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
New data show commercially insured patients face increasingly high cost sharing for brand medicines
Payers subject 80% of new RA and MS patients to utilization management restrictions
PhRMA submits comments to CMS on Medicaid proposed rule
New rule makes it harder for patients to lower their out-of-pocket costs
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
Addressing barriers that inhibit value-based contracts
New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
Guest post: Sharing discounts and rebates is the right thing to do
Survey shows out-of-pocket costs top health care concern for voters
Four reasons why the radical Pelosi Plan is the wrong approach
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
Three things to know about the Part D GAO report
Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices
How the rebate rule would help reduce patients’ out-of-pocket costs
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
Six policy solutions to help patients afford their insulin
Five key facts about the market for insulins
OIG proposed rule could help strengthen the Part D market
Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
OptumRX: Sharing rebates with patients is “worth it”
New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis
New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions
10 things you should know about medicine spending and costs
Six key facts about the market for insulins
Americans want to know more than just the list price of a medicine—and we’re answering their call
What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
Number of value-based contracts continues to rise
69 percent of patients abandon medicines when cost sharing is more than $250
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs
Pass-through rebates do not violate non-interference clause but they do increase savings for seniors
Medicare Part D cliff ahead
Patients with a deductible have seen their out-of-pocket costs for brand medicines increase 50 percent since 2014
Part D cliff looms for seniors, as program stability could be in jeopardy
ICYMI: Analysis finds higher outpatient drug spending at 340B hospitals
Event tomorrow: Improving patient access to lifesaving medicines
Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually
New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
Event tomorrow: Making the biopharmaceutical supply chain work for patients
Reality check: Value-based contracts are good for patients
Patients pay the price when hospitals mark up cancer medicines
Advance price notification: A transparency measure that fails patients
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Copay coupons can help ease patients’ out-of-pocket costs
Oregon’s HB 4005 fails to deliver savings for patients
PhRMA launches new consumer-facing Let’s Talk About Cost website
PhRMA urges CMS to share the savings with seniors
Clarity around anti-kickback statute needed to promote innovative payment arrangements
NHE Data: Medicine spending grew just 1.3 percent in 2016
New report shows better diabetes management saves money and improves patient outcomes
4 things to know about the QuintilesIMS drivers of medicine spending in the U.S. report
Why won’t the insurance industry tell the truth about medicine costs?
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
Recent administration actions undermine patient assistance programs
Out-of-Pocket Costs
Medicaid
Recent administration actions undermine patient assistance programs
Recent administration actions undermine patient assistance programs